TALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Study Results of JNJ-78278343 (pasritamig) in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 50/2025 December 14, 2025
- GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial December 12, 2025
- MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors December 12, 2025
- Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors December 11, 2025